We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in development for MDS and AML. We are also developing ME-344, a novel mitochondrial inhibitor, and PWT143, a highly selective PI3K delta inhibitor.
[ Read more ]
MEI Pharma Advances Clinical Study of Mitochondrial Inhibitor ME-344 in Small Cell Lung and Ovarian Cancers [ October 29, 2014 ]
MEI Pharma Reports Fiscal Year 2014 Results [ September 9, 2014 ]
MEI Pharma Completes Enrollment in Randomized Phase II Clinical Trial of Pracinostat in Front Line MDS
[ September 2, 2014 ]
Click here for our 2014 Annual Review